Blood tests could reveal who benefits from immunotherapy

NCT ID NCT05091190

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how well immunotherapy works in people with advanced lung or head and neck cancers. Researchers will take blood samples before and after treatment to measure how the body clears the drug and how tumor cells in the blood change. The goal is to find markers that predict who will respond best to immunotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

immunotherapy

What this could lead to

If successful, this could help doctors predict which patients will benefit from immunotherapy, leading to more personalized cancer treatment.

What could go wrong

This is an observational study with only 75 participants, so results may not apply to all patients. It measures biomarkers, not direct treatment outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Croix Rousse Hospital

    Lyon, France

  • Lyon Sud Hospital

    Pierre-Bénite, France